In light of the continued impact from SARS-CoV-2, the virus responsible for COVID-19, we have seen an increasing demand for assay development services as well as essential reagents. Rapid diagnostic tests are critical tools for screening at-risk populations and managing the spread of the outbreak, and we are actively helping in this fight.
nanoComposix is fully equipped to support new lateral flow assay development projects. Our team of experts can help develop an early stage point of care test from concept to prototype in as little as 4 weeks. Learn more about our Lateral Flow Assay Development capabilities.
nanoComposix can assist in all phases of lateral flow device manufacturing. From R&D to GMP, nanoComposix contract manufacturing department can help produce the material needed to support your product. We support R&D, pilot runs, gap manufacturing and are equipped to produce up to 10 million lateral flow tests each month under our ISO 13485:2016 certified Quality Management System*. Contact us for a quote.
nanoComposix has extensive experience in the LFA serological space, and has worked with both private corporations and government agencies (e.g. CDC, NIAID, NIH, etc.) to develop lateral flow diagnostics for infectious diseases, such as: cytomegalovirus infection, hepatitis C, hepatitis E, Lyme disease, paragonimiasis, loa loa filariasis, and tuberculosis. We are now completing the development of a serological assay for COVID-19 that measures both the IgM and IgG response in whole blood. nanoComposix has the rights to earmark certain tests for white label distribution. Contact us to learn more.
Development of sensitive lateral flow assays requires high performance, robust gold particles, and our BioReady gold reagents are a key component for maximizing the sensitivity and reliability of visual detection point of care tests.
Gold nanoshells can dramatically increase the sensitivity of lateral flow assays as each particle is 30× more strongly colored than 40 nm gold. The dramatic increase in color means that fewer binding events are required in order to see a result at the test line in a lateral flow assay. Learn more about the nanoshell advantage.
*Specific to 4878 Ronson Ct. Suite J and 4888 Ronson Ct. Suite B
